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Highlights
x A literature review dealing with medical treatment of vascular prosthesis 
infections was performed.
x The microbiological epidemiology of vascular prosthesis infections was 
highlighted.
x Indications and modalities of empirical antibiotherapy are proposed.
x Documented antibiotherapy of vascular prosthesis infections is described.
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ABSTRACT
More than 400 000 vascular grafts are inserted annually in the USA. Graft insertion 
is complicated by infection in 0.5–4% of cases. Vascular graft infections (VGIs) are 
becoming one of the most frequent prosthesis-related infections and are associated
with considerable mortality, ranging from 10–25% within 30 days following the 
diagnosis. Treatment of VGI is based on urgent surgical removal of the infected graft 
followed by prolonged antibiotherapy. Data regarding the best antibiotherapy to use 
are lacking since no well designed trial to study antimicrobial treatment of VGI exists. 
Moreover, since VGIs demonstrate very specific pathophysiology, guidelines on 
other material-related infections or infective endocarditis treatment cannot be entirely 
applied to VGI. A French multidisciplinary group gathering infectious diseases 
specialists, anaesthesiologists, intensivists, microbiologists, radiologists and vascular 
surgeons was created to review the literature dealing with VGI and to make some 
proposals regarding empirical and documented antibiotic therapy for these 
infections. This article reveals these proposals.
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1. Introduction
Due to advances in surgical techniques and increased possibilities for interventional 
radiology, the number of patients with vascular implants is constantly on the rise [1]. 
Prosthetic vascular graft infections (PVGIs) are among the most serious
complications associated with these procedures. Their frequency, ranging from 1–
5% of patients, varies depending on the anatomical implantation site, the biomaterial 
used and the patient’s co-morbidities. The mortality rate is estimated to be 10–25% 
within 30 days after the diagnosis and almost 50% after 1 year, and the risk of 
amputation is estimated at 4–14% [2]. However, there are very few validated data on 
the best medical treatments for these infections. A focus group composed of French 
vascular surgeons, anaesthesiologists, microbiologists, intensivists, radiologists and 
infectious diseases specialists was conducted to review the literature on the subject 
and to formulate proposals for anti-infective therapies for PVGIs.
2. Methodology
This study relates to aortic (chest and abdominal) and peripheral PVGIs, including 
prosthetic arteriovenous fistula infections and axillofemoral bypass graft infections. 
Venous or arterial catheter infections, endovascular stimulation material infections 
and autologous graft infections were excluded.
A French and English literature search was conducted through PubMed for the 
period 1 January 1991 to 1 March 2013 using a selection of keywords from the 
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Medical Subject Heading (MeSH) database as well as other unreferenced keywords. 
From the 9188 references thus selected, the following were excluded: series with 
less than 10 cases; in vitro studies; and incomplete or insufficiently documented 
series. Some animal studies were retained for the analysis when they were 
considered to be sufficiently informative. Series on arteriovenous fistula infections 
carried out on bovine carotid grafts were also excluded. The bibliographic references 
for all publications selected were reviewed. All of the studies that were retained were 
reviewed using the grid proposed by the Society for Vascular Surgery [3]. The 
recommendations are graded in accordance with the Haute Autorité de Santé 
(French Health Authority) methodology sheet from December 2010 (Table 1) [4]. In 
the absence of data, they correspond to recommendations based on a professional 
consensus (expert opinion) within the Working Group. Forty-six clinical studies were 
thus selected for analysis [5–50]. There were 43 cohort studies, with the number of 
patients ranging from 11 [8,19,21] to 187 [32] (mean, 49; median, 32) and a case–
control study involving 51 cases, for a total of 102 controls [34]. Four animal studies 
were also retained for analysis [51–54].
3. Empirical antibiotic therapy
3.1. Rationale
3.1.1. Microbiological information
The microbiological epidemiology of PVGIs is broken down as follows: 
Staphylococcus aureus, 20–53%; Enterobacteriaceae, 14–41%; coagulase-negative 
staphylococci (CoNS), 15%; Pseudomonas aeruginosa, Streptococcus sp. and
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Enterococcus sp., 10–15%; polymicrobial infection, 20%; obligate anaerobic bacteria 
(always associated with other bacteria), 5%; and yeast, 1–2%.
3.1.2. Indication
In the study by Legout et al. [33], the proportion of intra-operative samples with 
positive culture did not differ between patients who did or did not receive antibiotics 
before revision surgery, i.e. 38/43 vs. 40/42, respectively (P = 0.4). However, 
patients who received antibiotherapy prior to surgery were operated within the first 
48 h of treatment, and these results do not rule out the possible loss of 
microbiological information for patients treated >48 h prior to surgery, nor do they 
allow for the recommendation of empirical antibiotic therapy for all PVGI situations.
The issue of non-prescriptive empirical antibiotic therapy arises only when the 
patient has not received antibiotics prior to admission and when the expected time 
between diagnosis or suspicion and the revision surgery is short. No data are 
available to define the acceptable length of the expected timeframe for revision 
surgery beyond which empirical antibiotic therapy should be initiated. Ideally, this 
should be decided on a case-by-case basis as part of a multidisciplinary
consultation.
3.1.3. Choice of antibiotics
3.1.3.1. Impact of the biofilm
Biofilm developed on the vascular prosthesis plays a particular role in the difficulties 
encountered in treating PVGIs. Biofilm is formed by surface-associated communities 
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of micro-organisms embedded in an extracellular matrix that acts as both a barrier 
against antibiotic penetration and protection against host defences [55]. Moreover, 
bacteria express a distinct metabolic pathway within the biofilm [56]. Whilst
planktonic bacteria found outside the biofilm or in the very top layers of it display 
active metabolism and are therefore fully sensitive to antibiotics that mainly impair
bacterial mechanisms of replication, bacteria embedded deeply in a mature biofilm 
demonstrate very slowed-down metabolic pathways and a decreased efficacy of 
antibiotics [56,57]. In this context, curing PVGIs with antibiotics alone without 
removal of the infected device therefore seems elusive.
There are very few data, if any, regarding the efficacy of antibiotics on infected 
vascular graft biofilm. An in vitro study evaluated the impact of various antimicrobial 
agents on staphylococcal adherence on Dacron© or polytetrafluoroethylene (PTFE). 
In this model, daptomycin and rifampicin were the two best agents to eradicate 
staphylococcal biofilm, whereas vancomycin and ceftriaxone failed to sterilise it [58].
Other authors investigated the capabilities of various antibiotics to penetrate biofilm 
formed on other medical devices. Rifampicin is probably the antimicrobial agent that 
demonstrated the best activity on staphylococcal biofilm [54,59–63]. When in 
combination, fosfomycin has been found to enhance the antimicrobial activities of 
many antibiotics in meticillin-resistant S. aureus (MRSA) biofilm [64]. Daptomycin 
has also demonstrated interesting capacities in biofilm penetration [65], and some 
studies revealed a higher activity against stationary phase staphylococci than 
vancomycin [66]. However, the clinical relevance of all these in vitro data is still 
lacking and the therapeutic choice of the antimicrobial chemotherapy to use to treat 
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PVGIs cannot be only based on such biofilm penetration criteria, highlighting that
clinical studies and data are required.
3.1.3.2. Gram-positive cocci
The prevalence of MRSA has steadily declined in Europe since 2001 but remains 
>20%. The situation is different for CoNS, with resistance to E-lactams [67],
glycopeptides (including teicoplanin) [68] and, more recently, linezolid [69] steadily 
on the rise.
The risk factors associated with meticillin-resistant staphylococci (MRS) (S. aureus
or CoNS) in PVGI were examined in a retrospective study [41], which determined 
that the proportion of PVGIs caused by MRSA was 16%. The only factor identified 
was the existence of hypertension, but this relationship could not be explained. 
Given the important role of staphylococci in PVGIs, the significant proportion of 
MRSA and the absence of clinical risk factors validated by the meticillin resistance, it 
is recommended that the spectrum of empirical antibiotic therapy for PVGIs should 
systematically cover MRSA.
Anti-Gram-positive antibiotics used in empirical antibiotic therapy for PVGIs should 
ideally be bactericidal against bacteria both in the stationary growth phase and when
growing exponentially, and they should have a spectrum that covers MRS [including 
strains whose glycopeptide minimum inhibitory concentrations (MICs) are 
mg/L], good tissue distribution (including biofilm), an anti-adhesion effect and a good 
safety profile (including a kidney safety profile) that is compatible with the 
characteristics of patients with PVGIs. Considering these elements, linezolid and 
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tigecycline are less than ideal due to their solely bacteriostatic action and their failure 
to demonstrate their benefits in bacteraemic patients and/or in patients with severe 
infection; the same applies for teicoplanin [67], the anti-CoNS spectrum of which no 
longer appears to be currently adapted to the empirical treatment of prosthetic 
infection [67]. Vancomycin poses the problem of its nephrotoxic potential [70].
Daptomycin has a profile that is adapted to all of these prerequisites, but it does not 
have an approval for this type of use [71].
3.1.3.3. Gram-negative bacilli
Bacterial ecology is highly variable from one health facility to another, and as such it 
is difficult to recommend a standardised anti-Gram-negative bacilli empirical 
antibiotic therapy. The empirical prescription of amoxicillin/clavulanic acid appears 
inadequate because of the increasing prevalence of resistant Escherichia coli, 
exceeding one-third of strains [72]. The combinations piperacillin/tazobactam and 
ticarcillin/clavulanic acid have an advantage over cephalosporins because they cover 
obligate anaerobes, including Bacteroides fragilis.
The increase in carbapenemase-producing bacteria in human pathology restricts the 
use of carbapenems to severe infections and/or when the patient has multidrug-
resistant bacteria [73].
Aminoglycosides may be useful to intensify bactericidal activity and to rapidly reduce 
the bacterial inoculum, but they expose patients to the risk of nephrotoxicity, 
particularly patients with chronic renal failure or cirrhosis. The impact of their use on 
mortality varies: one study found no benefit of aminoglycosides on mortality rates
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[41], whereas a separate study found that aminoglycosides might reduce mortality 
when used for patients in intensive care (59% vs. 27%; P = 0.07 in multivariate 
analysis) [42].
3.2. Recommendations
It is recommended that the use of empirical antibiotic therapy should be limited to 
suspected or known cases of PVGI for which it does not seem reasonable to wait for 
surgical microbiological sample results. Such situations include severe sepsis, septic 
shock, and instances in which the clinical and/or radiological signs indicate a 
mechanical complication of infectious origin, such as an a eurysmal rupture or 
anastomotic disunion (C-III). Two different sets of blood cultures should 
systematically be performed prior to empirical antibiotherapy.
Adaptation is necessary after receiving the microbiological results from blood 
cultures or surgical samples. Such ‘de-escalation’ should be performed as quickly as 
possible to limit the selection pressure for resistant strains that is induced by this 
broad-spectrum antibiotic therapy (B-III).
Table 2 presents proposals for empirical antibiotic therapy depending on the clinical 
situation (C-III).
The potential severity of PVGIs, their frequent association with bacteraemia, and the 
need for sufficient concentrations at the site of the infected material 
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interface/periprosthetic tissue are good arguments for parenteral administration and 
the use of high dosages (C-III).
4. Documented antibiotic therapy
The following proposals reflect the prerequisites outlined above (good diffusion in the 
biofilm, activity against slowly metabolising strains, high tolerance, need for 
bactericidal treatment) and result from an analysis of the PVGI literature and the 
most recent recommendations for the treatment of prosthetic valve endocarditis
[34,74–76]. Although PVGIs cannot be entirely likened to infective endocarditis (IE), 
these two types of infection have many points in common, including infection of 
endovascular material with production of biofilm, patients with multiple co-
morbidities, frequently impaired renal function, and similarity of causative micro-
organisms, with the exception of Enterobacteriaceae and obligate anaerobic bacteria 
that are often encountered in cases of PVGI but are rare in IE.
Blood cultures and/or periprosthetic collection punctures can serve to document the 
infection prior to surgery. The following recommendations therefore distinguish two 
situations: pre-operative and post-operative antibiotic therapy. For the post-operative 
part, two situations are distinguished: optimal management (excision of the entire 
infected prosthesis and the surrounding infected tissue); and suboptimal surgery (all 
or part of the prosthesis left in place). In the absence of pre-operative 
documentation, the antibiotic therapy recommendations are outlined in Section 3.
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There are no data regarding the impact of the surgical procedure performed on the 
antibiotherapy. It is not known whether the type of biomaterial used for the vascular 
reconstruction after infected graft removal (autogenous venous graft, cryopreserved 
arterial allograft, prosthetic graft) or the surgical procedure performed (extra-
anatomical or in situ reconstruction) influence the choice or duration of antibiotic 
treatment. It is therefore recommended to apply the same medical treatment for all of 
the different surgical techniques (C-III).
It is also not known whether the anatomical site or the type of infected material 
impact the choice of antibiotherapy. In the literature, peripheral lower limb VGI and 
aortic VGI are often individualised but only for the surgical procedure and not for the 
medical treatment. Prosthetic dialysis arteriovenous graft infections have also been 
specifically studied but only in three studies [77–79], and data dealing with antibiotics 
are too scarce to propose specific medical treatment for these infections. Thus, it is 
recommended to adopt the same medical treatment for all the different types of 
PVGIs (C-III).
The dosages and modes of administration of the various compounds mentioned are 
provided in Table 3. Generally (B-III):
x In the event of reliable pre-operative documentation (deep sampling 
performed through healthy dermal route or positive blood culture), antibiotic 
therapy should target only the pathogen or pathogens found.
x Post-operative re-evaluation of this antibiotic therapy should be carried out in 
light of the intra-operative sampling results.
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x Surgical treatment should be performed as quickly as possible because of the 
extreme severity of PVGIs in order to facilitate the efficacy of the anti-infective 
therapy. This is particularly important in cases of micro-organisms that are 
difficult to treat, such as multiresistant bacteria, enterococci, P. aeruginosa
and yeasts.
4.1. Staphylococcal infections
4.1.1. Rationale
Although not new [80], data regarding the efficacy of meticillin derivatives are still 
valid [81] and the use of these derivatives remains highly recommended as the first-
line treatment for severe meticillin-sensitive S. aureus infections [34,75,76,82]. In the 
case of penicillin allergy without allergy to cephalosporins, the choice will be between 
cefazolin, vancomycin and daptomycin. In the case of allergy to all E-lactams, the 
choice will be between vancomycin and daptomycin [34,81,83–90].
Treatment of MRSA infections is difficult. Vancomycin is established by usage as the 
compound of choice, although failures are reported, particularly in cases of high 
vancomycin MICs (1.5 mg/L) [91,92].
Given that PVGIs are severe infections on foreign materials, addition of an 
aminoglycoside, preferably gentamicin, is justified [59,93–95].
Addition of rifampicin is attractive because of its large diffusion capacity, anti-
adhesion potency and preserved bactericidal activity despite the presence of a 
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biofilm [59,60,96]. Its use is also correlated with a better prognosis in osteoarticular 
staphylococcal infections [97]. Its prescription as monotherapy is strongly 
discouraged, as is its use in bacteraemic patients [98], owing to the rapid emergence 
of a resistant strain of bacteria. There are no data regarding the use of rifampicin in 
PVGIs, but the pharmacological, clinical and experimental data argue in favour of its 
use. Therefore, in the treatment of staphylococcal PVGIs, it is advisable to add 
rifampicin to the treatment after vascular surgery and certainty of negative blood 
cultures.
Daptomycin exhibits interesting bactericidal activity within the biofilm [58,99]. It is 
approved for bacteraemia and right-sided endocarditis caused by S. aureus at a 
dose of 6 mg/kg/day in a single injection [100]. However, there appears to be a 
possibility of decreased staphylococci susceptibility during treatment [101] and a 
greater number of microbiological failures compared with comparators [100],
suggesting that the dose of 6 mg/kg/day may be insufficient. Some authors have 
also shown that higher doses (8–12 mg/kg/day) do not pose any particular tolerance 
problems [102,103], although it is not known whether this increase in dosage 
changes the prognosis of infections. However, no data are available regarding the 
use of daptomycin in the treatment of PVGIs, and the use of this compound as first-
line therapy should be subject to a multidisciplinary approach when the 
staphylococcal strain is sensitive to meticillin and vancomycin (MICs < 1.5 mg/L). In 
staphylococcal infections caused by strains with vancomycin MICs PJ/WKH
use of daptomycin is advised, at high doses, in combination with gentamicin for the 
first 3 days of treatment, followed by rifampicin. Daptomycin MICs for the isolated 
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strain should be documented. It has indeed been shown that sensitivity to 
daptomycin may decrease when the vancomycin MIC is elevated [104,105].
No scientifically valid data provide a basis for preferring one compound to another for 
PVGIs caused by glycopeptide-resistant staphylococci. However, daptomycin is the 
compound for which data related to use on foreign material [106] and IE [100] are 
the most documented. To improve efficacy and reduce the risk of emergence of 
strains with reduced susceptibility to daptomycin during treatment, it should be 
combined with another antibiotic, preferably gentamicin [107] or rifampicin [108].
For other antistaphylococcal agents, no data are available for this type of infection 
and their use should be considered only on a case-by-case basis, in combination, in 
the absence of an alternative and following a multidisciplinary opinion.
4.1.2. Recommendations
Therapeutic proposals for PVGIs caused by staphylococci (S. aureus or CoNS) are 
presented in Tables 4 and 5.
4.2. Streptococcal infections
4.2.1. Rationale
There is no study specific to the treatment of streptococcal PVGIs. Therefore, the
following recommendations stem from extrapolations from comparable clinical 
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situations for which reliable data are available. Amoxicillin remains the antibiotic of 
choice for streptococcal infections [34,75,82,109–111].
The use of aminoglycosides for treating severe streptococcal infections is currently 
under debate because of their potential toxicity [112]. Analysis of the literature does 
not support any conclusion regarding their usefulness [113–116]. Their use in the 
first days of treatment to reduce bacterial inocula appears to be justified.
Post-operatively, this benefit is more questionable: the bacterial inoculum is reduced 
by surgery, and the remaining bacteria are located in the periphery of the prosthesis, 
in an extravascular position, an area in which the diffusion of aminoglycosides is very 
limited. If vancomycin is used, co-administration of gentamicin is not recommended 
because of the low level of evidence regarding its use in this context and the risk of 
renal toxicity associated with this combination. When used, gentamicin is given in a 
single daily dose [93].
The effectiveness of other antibiotics with antistreptococcal activity in PVGI 
treatment has not yet been established.
4.2.2. Recommendations
4.2.2.1. Pre-operative treatment
Determination of MICs of amoxicillin, cefotaxime and/or ceftriaxone, or even 
vancomycin, should be obtained, particularly in cases of viridans streptococci 
infection (B-III). Amoxicillin is the recommended treatment for streptococcal PVGIs 
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that are sensitive to this compound, with dosages ranging from 100 mg/kg/day 
(streptococci for which the amoxicillin MIC is <0.125 mg/L) to 200 mg/kg/day (MIC 
0.125 mg/L) divided into four to six injections (B-III). Gentamicin can be added, for a 
maximum period of 3 days, at a dose of 3–8 mg/kg/day (C-III).
Vancomycin is the antibiotic of choice (B-III) when susceptibility to all E-lactam 
antibiotics is decreased or in the case of allergy to all members of this therapeutic 
class. Determination of the vancomycin MIC is therefore imperative. Combination 
with gentamicin is not systematic; it is only considered in the event of signs of severe 
sepsis or septic shock, and its use is then restricted to 3 days (C-III).
4.2.2.2. Post-operative treatment
4.2.2.2.1. For optimal surgical treatment
Post-operative treatment is the same as that recommended for pre-operative 
treatment (B-III). The duration of treatment is 6 weeks post-operatively, parenterally
(C-III).
4.2.2.2.2. For suboptimal surgical treatment
Antibiotic treatment is the same as in the previous situation for 6 weeks post-
operatively (B-III). Subsequently, switching to oral amoxicillin can be considered (C-
III).
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4.3. Enterococcal infections
4.3.1. Rationale
In the absence of high-level resistance to gentamicin, the combination of amoxicillin
+ gentamicin is synergistic and bactericidal [117,118]. Extrapolation of data 
regarding endocarditis would serve to restrict the duration of use of gentamicin [119].
Post-operatively, due to the decrease of inoculum, treatment with aminoglycoside is 
temporally shortened.
Experimental data have shown that the ampicillin + ceftriaxone combination may act 
synergistically when used in the treatment of experimental endocarditis caused by 
Enterococcus faecalis [120,121]. Human clinical data also appear to confirm this
[122,123]. This combination could be an option in the case of significant toxicity of 
aminoglycosides or pre-existing renal insufficiency.
For PVGIs caused by vancomycin-r sistant enterococci, there is not yet enough 
solid evidence to recommend one compound over another [124]. Linezolid has 
sometimes been used [125,126], most often in combination with other compounds, 
but its prolonged use is difficult because of its neurological and haematological 
toxicity and potential risk of relapse [127,128]. Some experimental studies [129] or 
clinical cases [130] also reported the efficacy of daptomycin in this indication, but the 
emergence of resistant strains [131,132] makes its use problematic. However, some 
in vitro data appear to indicate a real synergy between daptomycin and rifampicin or 
ampicillin against enterococci [133,134]. Monitoring of a cohort of 159 patients (90% 
bacteraemic) treated with daptomycin for enterococcal infection, 115 of whom were 
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resistant to vancomycin, showed a cure rate of 44% [135]. It is not possible to be 
categorical regarding the choice of the compound to be used in glycopeptide-
resistant PVGIs caused by enterococci [136]. This choice must be made after 
multidisciplinary discussion.
4.3.2. Recommendations
4.3.2.1. Pre-operative treatment
Amoxicillin is the recommended treatment for PVGIs caused by susceptible
enterococci. The dose is 200 mg/kg/day divided into four to six injections (B-III). 
Gentamicin is used, in a single daily dose, for 7 days at a dose of 3–8 mg/kg/day if 
surgery is not performed before treatment (B-III).
In the case of allergy or resistance to amoxicillin, teicoplanin or vancomycin alone is 
recommended (B-III). In the case of resistance to glycopeptides, the susceptibility of 
enterococcus to daptomycin and lin zolid must be studied. The choice will be made 
following a multidisciplinary opinion (C-III).
4.3.2.2. Post-operative treatment
4.3.2.2.1. For optimal surgical treatment
Post-operative treatment is the same as that recommended for pre-operative 
treatment regarding amoxicillin or glycopeptides (B-III). Gentamicin is continued only 
for a maximum of 3 days (C-III). The duration of treatment is 6 weeks post-
operatively, parenterally, at the same dosage (C-III).
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4.3.2.2.2. For suboptimal surgical treatment
Antibiotic treatment is the same as in the previous situation for 6 weeks post-
operatively (C-III). Subsequently, oral amoxicillin relay, for an extended period, can 
be considered (C-III).
4.4. Enterobacteriaceae infections
4.4.1. Rationale
The benefit of combination therapy in infections caused by enterobacteria is 
controversial [137]. The synergistic effect and prevention of resistance has not been 
demonstrated by clinical studies [137–144]. However, the severity of PVGIs and the 
risk of severe systemic impact justify the initial combination of an aminoglycoside 
with a E-lactam for a short period of time [93].
4.4.2. Recommendations
Therapeutic proposals for PVGIs caused by Enterobacteriaceae are presented in 
Table 6.
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4.5. Pseudomonas infections
4.5.1. Rationale
On a compromised terrain and high inoculum, the slightest susceptibility to 
antibiotics and resistance make the treatment of PVGIs caused by Pseudomonas
difficult. The benefit of combination therapy that has not been shown by discordant 
and heterogeneous clinical studies [145–148] remains established by usage prior to
surgery and post-operatively.
4.5.2. Recommendations
4.5.2.1. Pre-operative treatment
Treatment is based on a E-lactam, and the choice is made according to the results of 
antibiotic susceptibility testing among ticarcillin, ceftazidime, piperacillin/tazobactam
and a carbapenem (excluding ertapenem) (B-III). An aminoglycoside (amikacin or 
tobramycin) is combined with it for 3 days (C-III). The aminoglycoside is replaced by 
fosfomycin beyond these 3 days if the surgery has not yet been performed (C-III). 
Fluoroquinolones should be reserved for post-operative oral relay (B-III).
4.5.2.2. Post-operative treatment
4.5.2.2.1. For optimal surgical treatment
Combination therapy is continued, with the E-lactam selected pre-operatively being 
used in conjunction with ciprofloxacin or fosfomycin, depending on antibiotic 
susceptibility testing (C-III). This combination therapy is continued for t3 weeks, for a 
total of 6 weeks post-operatively (C-III).
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4.5.2.2.2. For suboptimal surgical treatment
Multidisciplinary opinion (C-III).
4.6. Obligate anaerobic bacterial infections
4.6.1. Rationale
Metronidazole, which is consistently active against obligate anaerobes, particularly 
B. fragilis, is the compound of choice. Its absorption and exceptional diffusion allow 
its use as oral monotherapy [149]. Propionibacterium acnes, which is naturally 
resistant to imidazole, is susceptible to amoxicillin. Surgery is essential because
relapse when the prosthetic material is left in place is virtually systematic [150].
Clindamycin, in addition to the risk of Clostridium difficile colitis, does not have a 
satisfactory anti-anaerobic spectrum, particularly against B. fragilis, which limits its 
empirical prescription in cases of PVGI [149].
4.6.2. Recommendations
4.6.2.1. Pre-operative treatment
Metronidazole is the first-line treatment for obligate anaerobic infections apart from 
P. acnes. It may be administered orally or intravenously (B-III). PVGIs caused by P.
acnes are treated with intravenous amoxicillin (B-III). Monotherapy is sufficient (B-
III).
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4.6.2.2. Post-operative treatment
4.6.2.2.1. For optimal surgical treatment
The treatment is the same as pre-operative management (B-III). The total duration of 
treatment is 6 weeks (C-III).
4.6.2.2.2. For suboptimal surgical treatment
Suppressive oral amoxicillin treatment may be proposed for PVGIs caused by P.
acnes and following a multidisciplinary opinion (C-III). For other obligate anaerobes 
such as B. fragilis, the possibility of suppressive treatment should be evaluated after 
multidisciplinary consultation (C-III).
4.7. Polymicrobial infections
Susceptibility testing should be performed for each of the isolated bacteria. Several 
compounds may sometimes be necessary to cover all of the bacteria considered 
pathogenic. A multidisciplinary opinion is necessary (B-III). The presence of obligate 
anaerobes does not require metronidazole if one of the combination antibiotics is 
already active on these bacteria (B-III).
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5. Duration of treatment of bacterial prosthetic vascular graft 
infections and methods of administration
5.1. Rationale
Analysis of treatment duration from different studies is difficult to interpret because 
of: (i) the non-comparative nature of these studies; (ii) studies that do not include 
standardised durations or feature highly variable durations; and (iii) the use of a wide 
variety of compounds. In all of these studies, patients underwent surgery. The 
durations of antibiotic therapy are variable, ranging from 2 weeks after surgery
[15,31] to 6 months [30], or even lifelong [22]. Many studies report durations of 6 
weeks post-operatively [5,7,9,11–14,25,27,28,35,37] without the risk of relapse 
appearing greater than that encountered when the treatment period is longer. This 6-
week duration is the same as that proposed in the treatment of prosthetic valve 
endocarditis [34,82].
5.2. Recommendations
The total duration of post-operative antibiotic therapy proposed for PVGIs is 6 weeks 
for optimal surgical treatment (C-III). It should be administered parenterally. When 
using compounds with good bioavailability (rifampicin, fluoroquinolones), oral 
administration is possible.
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6. Methods of administration of anti-infective agents
These methods are presented for normal renal and hepatic function in Table 3. In 
patients with renal or hepatic impairment, an adjustment may be required.
7. Suppressive antibiotic therapy
7.1. Rationale
In the absence of surgery, or in cases of suboptimal surgery, suppressive antibiotic 
therapy is administered. Its aim is to inhibit bacterial growth around the prosthesis, or 
what is left of it. By analogy with infections on osteoarticular material [151], it is 
assumed that in the stationary growth phase, bacteria remain on the material that 
cannot be eliminated by intensive antibiotic therapy. Even with very high dosage and 
very long duration, antibiotherapy alone is not supposed to cure PVGIs [152]. For 
instance, a recent study dealing with aortic endograft infection demonstrated that all 
of the patients who did not undergo ndograft removal died during follow-up [49].
Suppressive treatment is only conceivable in the case of documented infection. In 
cases of periprosthetic abscess, radiological drainage should be performed if 
possible to reduce the bacterial inoculum as much as possible. No formal studies 
currently serve to validate this approach.
7.2. Recommendations
Suppressive antibiotic therapy is administered in the absence of surgery or in the 
case of suboptimal surgery (C-III). This antibiotic therapy will follow a 6-week period 
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of intensive antibiotic therapy (B-III). It should therefore be easy to administer 
(orally), well tolerated and feasible as monotherapy. The choice of compound used 
should result from a multidisciplinary approach (B-III).
8. Specific case of fungal infection
8.1. Rationale
This essentially relates to yeast infections, such as Candida, in the context of 
bacterial co-infections. The therapeutic choice is made between amphotericin B 
derivatives (liposomal or lipid complex), azoles (mainly fluconazole) and 
echinocandins. The theoretical prerequisites are fungicidal treatment with activity 
preserved in the biofilm, anti-adhesion effect, proper dissemination to the infectious 
site and good tolerance. For this last reason, amphotericin B, which is nephrotoxic, is 
not recommended because of the frail nature of the patients.
Echinocandins have a good safety profile (including renal), in vitro fungicidal activity 
against yeasts, and good action in the case of existence of biofilm [153]. Their use is 
recommended by several scientific societies as a first-line treatment of moderate-to-
severe infections [154]. One key disadvantage of using echinocandins is that they 
are available only for parenteral administration. There is a restriction on the use of 
micafungin (risk of liver tumours observed in a mouse model).
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8.2. Recommendations
Isolation of the fungus and antifungal susceptibility testing are essential. An 
echinocandin (caspofungin, micafungin or anidulafungin, if available) is used as a 
first-line treatment for 10 days post-operatively and/or 10 days after the last positive 
blood culture for Candida (C-III). If the strain is susceptible, if blood cultures are 
negative for t10 days and if the clinical situation has stabilised, an oral relay 
treatment with fluconazole may be taken on Day 10: loading dose of 800 mg on the 
first day followed by a one-time dose of 400–800 mg/day (B-III). The duration of 
treatment is t6 weeks post-operatively and 3 months in cases involving a 
periprosthetic abscess (C-III).
9. Conclusions
PVGIs are infections burdened with heavy rates of morbidity and mortality, the
frequency of which are rising because of surgical advances and endovascular 
techniques that make it possible to implant an increasing number of prostheses. No 
data currently provide solid evidence regarding the antimicrobial therapy to be 
administered to patients suffering from PGVIs. A comprehensive literature review 
was therefore conducted. We hope that the proposals resulting from this analysis will 
help practitioners with regard to the care of these patients. It is increasingly vital to 
validate these proposals by means of further research investigating this issue, and 
we hope that the results of such studies will soon be available.
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Table 1
Levels of evidence and grades of recommendations used
Level of evidence provided by the literature Grade of recommendations
Level I
High-quality randomised controlled trials
Meta-analysis of randomised controlled trials
Decision analysis based on well conducted studies
A
Established scientific 
evidence
Level II
Low-quality randomised controlled trials
Non-randomised, well conducted comparative 
studies
Cohort studies
B
Scientific presumption
Level III
Case–control studies
Level IV
Comparative studies with significant biases
Retrospective studies
Case series
C
Low level of evidence
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Table 2
Empirical antibiotic therapy for prosthetic vascular graft infections (PVGIs) depending 
on the clinical situation (C-III)
Clinical situation In the absence of allergy to E-lactams In the case of allergy to penicillin
PVGI with sepsis
without signs of 
severity
or known colonisation,
no history of MDR
bacterial infection
Piperacillin/tazobactam
+ vancomycin or daptomycin
a
± gentamicin
Cefotaxime or ceftriaxone or 
cefepime or aztreonam
+ metronidazole
+ vancomycin or 
daptomycin a
± gentamicin
PVGI with sepsis, 
signs of severe 
sepsis
and/or known 
colonisation
or previous infection 
with ESBL-GNB b
Imipenem or meropenem or 
doripenem
+ vancomycin or daptomycin
a
± gentamicin
Fosfomycin
+ metronidazole
+ vancomycin or 
daptomycin a
± gentamicin
MDR, multidrug-resistant; ESBL-GNB, extended-spectrum E-lactamase-producing 
Gram-negative bacillus.
a No approval for this indication.
b Resistant to third- or fourth-generation cephalosporins on antibiotic susceptibility 
testing.
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Table 3
Dosage, route and rate of administration of anti-infectives in prosthetic vascular graft 
infections
Compound Dosage Route and rate of 
administration
Amikacin 15–30 mg/kg/day One i.v. infusion over 30 
min
Amoxicillin 100–200 mg/kg/day Six i.v. infusions over 30 
min
or i.v. via infusion pump
Amoxicillin/clavulanic 
acid
100–200 mg/kg/day of 
amoxicillin
Six i.v. infusions over 30 
min (2 g vials)
Caspofungin 70 mg the first day and then 50 
mg/day (weight <80 kg) or 70 
mg/day (weight 80 kg)
One i.v. infusion over 1 h
Cefazolin 60–80 mg/kg/day Six i.v. infusions over 30 
min
or i.v. via infusion pump a
Cefotaxime 150 mg/kg/day Six i.v. infusions over 30 
min
or i.v. via infusion pump a
Ceftazidime 100 mg/kg/day Four i.v. infusions over 
30 min
or i.v. via infusion pump a
Ceftriaxone 50 mg/kg/day One to two i.v. infusions 
over 30 min
Ciprofloxacin 1500–2000 mg/day (orally)
or 800–1200 mg/day (i.v.)
Two to three oral doses b
or two to three i.v. 
infusions over 30 min b
Page 55 of 64
A
cc
ep
te
d 
M
an
us
cr
ip
t
55
Cloxacillin or oxacillin 200 mg/kg/day Six i.v. infusions over 30 
min
or i.v. via infusion pump 
on three syringes over 
8 h a
Daptomycin 8–10 mg/kg/day One i.v. infusion over 2–
30 min
Doripenem 3 g/day Three i.v. infusions over 
4 h
or i.v. via infusion pump 
(500 mg in 50 mL to 12 
mL/h)
Fluconazole 800 mg on the first day and 
400–800 mg/day
One oral dose
or one i.v. infusion over 2 
h c
Fosfomycin 150–200 mg/kg/day Three to four i.v.
infusions over 3–4 h
Gentamicin 3–8 mg/kg/day One i.v. infusion over 30 
min
Imipenem 3 g/day Three i.v. injections over 
30 min
Levofloxacin 500–1000 mg/day One oral dose
or one i.v. infusion over 
30 min b
Meropenem 3–6 g/day Three i.v. infusions over 
30 min
Metronidazole 1500 mg/day Three oral doses
or three i.v. infusions 
over 30 min c
Micafungin 100 mg/day One i.v. infusion over 1 h
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Ofloxacin 400–600 mg/day Two oral doses
or two i.v. infusions over 
30 min b
Piperacillin/tazobactam 150–200 mg/kg/day of 
piperacillin
Three infusions over 4 h
Rifampicin 10–20 mg/kg/day Two oral doses (fasting)
or two i.v. infusions over 
30 min c
Teicoplanin d 8–12 mg/kg/12 h for 3 days 
and then 8–12 mg/kg/day
Slow i.v., i.m. or
subcutaneous
Ticarcillin 250 mg/kg/day Three i.v. infusions over 
30 min
or i.v. via infusion pump a
Vancomycin d 40–60 mg/kg/day i.v. via infusion pump a
i.v., intravenous; i.m., intramuscular.
a Begin with a loading dose equal to one-quarter of the total daily dose, to be 
administered over 30 min via i.v. infusion, except for vancomycin for which the
duration of administration of the loading ose is longer: 15 mg/kg loading dose to be 
infused over 1 h (1 g) or 1 h 30 min (1.5 g).
b The highest dosages of fluoroquinolones are to be considered when combined with 
rifampicin owing to the enzyme induction properties of the latter.
c Preference should be given to oral administration.
d Glycopeptide dosage: this will be done after 72 h for vancomycin and after the sixth 
infusion for teicoplanin (just before the infusion) and then once a week for the entire 
duration of the treatment.
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Table 4
Antibiotic therapy for prosthetic vascular graft infections caused by meticillin-
sensitive Staphylococcus sp.
In the absence of 
allergy to E-
lactams
In the case of 
allergy to 
penicillin
In the case of 
contraindication to E-lactams
Pre-operative 
treatment
Cloxacillin or 
oxacillin (B-III)
+
gentamicin a 3 
days (B-III)
Cefazolin or 
vancomycin or 
daptomycin (B-
III)
+
gentamicin a 3 
days (B-III)
Vancomycin or 
daptomycin (B-
III)
+
gentamicin a 3 
days (B-III)
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Post-
operativ
e 
treatmen
t
Optimal Cloxacillin or 
oxacillin (B-III)
+
gentamicin a 3 
days (C-III)
and then addition 
of rifampicin b in 
place of 
gentamicin (B-III)
relay with oral 
rifampicin + 
fluoroquinolone 
at Day 15 post-
operatively c (C-
III)
Duration of 
treatment, 6 
weeks post-
operatively (C-
III)
Cefazolin or 
vancomycin or 
daptomycin (B-
III)
+
gentamicin a 3 
days (C-III)
and then addition 
of rifampicin b in 
place of 
gentamicin (B-III)
relay with oral 
rifampicin + 
fluoroquinolone 
at Day 15 post-
operatively c (C-
III)
Duration of 
treatment, 6 
weeks post-
operatively (C-
III)
Vancomycin or 
daptomycin (B-
III)
+
gentamicin a 3 
days (C-III)
and then addition 
of rifampicin b in 
place of 
gentamicin (B-III)
relay with oral 
rifampicin + 
fluoroquinolone 
at Day 15 post-
operatively c (C-
III)
Duration of 
treatment, 6 
weeks post-
operatively (C-III)
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Suboptimal Cloxacillin or 
oxacillin (B-III)
+
gentamicin 3 days 
(C-III)
and then addition 
of rifampicin b in 
place of 
gentamicin (B-III) 
for 6 weeks post-
operatively (C-
III)
and then 
suppressive 
treatment d (C-
III)
Cefazolin or 
vancomycin or 
daptomycin (B-
III)
+
gentamicin 3 days 
(C-III)
and then addition 
of rifampicin b in 
place of 
gentamicin (B-III) 
for 6 weeks post-
operatively (C-
III)
and then 
suppressive 
treatment d (C-III)
Vancomycin or 
daptomycin
+
gentamicin 3 days
and then addition 
of rifampicin b in 
place of 
gentamicin (B-III) 
for 6 weeks post-
operatively (C-III)
and then 
suppressive 
treatment d (C-III)
a Dosage of 3–8 mg/kg/day in a single daily dose. In patients with severe infection 
with the risk of increased volume of distribution (severe sepsis or even septic shock, 
mechanical ventilation, presence of oedema, etc.), preference should be given to 
higher doses (5–8 mg/kg/day). The rate of administration and dosages are to be 
adapted to residual concentrations.
b After ascertaining that blood cultures are negative.
c Only in the case of good clinical evolution, if susceptible to fluoroquinolones and in 
the absence of post-operative bacteraemia. No other oral relay is recommended (C-
III).
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d To be determined based on susceptibility testing and following a multidisciplinary 
opinion.
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Table 5
Antibiotic therapy for prosthetic vascular graft infections caused by meticillin-resistant 
Staphylococcus sp.
Vancomycin MIC < 1.5 
mg/L
Vancomycin MIC 1.5 
mg/L
Pre-operative treatment Vancomycin a (B-III) or 
daptomycin (C-III)
+
gentamicin 3 days (B-III)
Daptomycin (B-III)
+
gentamicin 3 days (C-III)
Post-
operative 
treatment
Optimal Vancomycin a (B-III) or 
daptomycin (C-III)
+
gentamicin 3 days (C-III)
and then addition of 
rifampicin b in place of 
gentamicin (B-III)
relay with oral rifampicin + 
fluoroquinolone at Day 15 
post-operatively c (C-III)
Duration of treatment, 6 
weeks post-operatively 
(C-III)
Daptomycin (B-III)
+
gentamicin 3 days (C-III)
and then addition of 
rifampicin b in place of 
gentamicin (B-III)
relay with oral rifampicin + 
fluoroquinolone at Day 15 
post-operatively c (C-III)
Duration of treatment, 6 
weeks post-operatively 
(C-III)
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Suboptimal Vancomycin (B-III) or 
daptomycin (C-III)
+
gentamicin 3 days (C-III)
and then addition of 
rifampicin in place of 
gentamicin (B-III) for 6 
weeks post-operatively 
(C-III)
and then suppressive 
treatment d (C-III)
Daptomycin (B-III)
+
gentamicin 3 days (C-III)
and then addition of 
rifampicin in place of 
gentamicin (B-III) for 6 
weeks post-operatively 
(C-III)
and then suppressive 
treatment d (C-III)
MIC, minimum inhibitory concentration.
a Equilibrium concentrations of vancomycin, 20–30 mg/L. Teicoplanin can be 
considered, as a relay, after ascertaining the susceptibility of the bacterial strain and 
if the clinical condition has stabilised (C-III).
b After ascertaining that blood cultures are negative.
c Only in the case of good clinical evolution, if susceptible to fluoroquinolones and in 
the absence of post-operative bacteraemia.
d To be determined based on susceptibility testing and after multidisciplinary opinion.
Page 63 of 64
A
cc
ep
te
d 
M
an
us
cr
ip
t
63
Table 6
Antibiotic treatment of prosthetic vascular graft infections caused by 
Enterobacteriaceae
In the absence of allergy to E-lactams In the case of allergy to penicillin
Pre-operative treatment Ceftriaxone or cefotaxime a
(B-III)
+
gentamicin 3 days b (C-III)
Aztreonam (C-III)
+
gentamicin 3 days (C-III)
Optimal Ceftriaxone or cefotaxime a
(B-III)
and then relay with 
fluoroquinolones c (C-III)
Duration of treatment, 6 
weeks post-operatively (C-
III)
Aztreonam (C-III)
and then relay with 
fluoroquinolones c (C-III)
Duration of treatment, 6 
weeks post-operatively 
(C-III)
Post-
operative 
treatment
Suboptimal Ceftriaxone or cefotaxime a
(B-III)
and then relay with 
fluoroquinolones c (C-III) 
for 6 weeks post-
operatively (C-III)
and then suppressive 
treatment d (C-III)
Aztreonam (C-III)
and then relay with 
fluoroquinolones c for 6 
weeks post-operatively 
(C-III)
and then suppressive 
treatment d
a Use of another narrower-spectrum E-lactam is possible based on the susceptibility 
testing data and following a specialist opinion.
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b The dose of gentamicin is between 5 mg/kg/day and 8 mg/kg/day. Higher doses 
are preferable in the case of septic shock (B-III).
c The relay is done 15 days post-operatively in the case of good evolution. It can also 
be done earlier in the case of good evolution when aztreonam is used. If bacteria are 
resistant to fluoroquinolones and nalidixic acid, continue with E-lactam antibiotics for 
6 weeks post-operatively (B-III).
d To be determined based on susceptibility testing and following a multidisciplinary 
opinion.
a.
